TY - JOUR
T1 - HIV peripheral neuropathy progression
T2 - Protection with glucose-lowering drugs?
AU - Evans, Scott R.
AU - Lee, Anthony J.
AU - Ellis, Ronald J.
AU - Chen, Huichao
AU - Wu, Kunling
AU - Bosch, Ronald J.
AU - Clifford, David B.
N1 - Funding Information:
This work was supported by National Institute of Health (NIH) grants including the Neurologic AIDS Research Consortium grant NS32228 from NINDS, the AIDS Clinical Trials Grant AI068636 from NIAID, and the Statistical and Data Management Center of the Adult AIDS Clinical Trials Group grant 1 U01 068634. The authors acknowledge the generous dedication of the many participants volunteering for the ALLRT study, and for the contributions of the contributing AIDS Clinical Trials Units, their investigators and staffs that collected the samples and clinical data used for this analysis.
Funding Information:
This work was supported by National Institute of Health (NIH) grants including the Neurologic AIDS Research Consortium grant NS32228 from NINDS, the AIDS Clinical Trials Grant AI068636 from NIAID, and the Statistical and Data Management Center of the Adult AIDS Clinical Trials Group grant 1 U01 068634.
PY - 2012/10
Y1 - 2012/10
N2 - The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR)=1.58, 95 % confidence interval (CI)=(1.08, 2.29), p=0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR= 2.16, 95 % CI=(1.21, 3.85), p=0.009) while use of glucoselowering drugs (non-insulin) was protective (OR=0.12, 95 % CI=(0.02, 0.83), p=0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.
AB - The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR)=1.58, 95 % confidence interval (CI)=(1.08, 2.29), p=0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR= 2.16, 95 % CI=(1.21, 3.85), p=0.009) while use of glucoselowering drugs (non-insulin) was protective (OR=0.12, 95 % CI=(0.02, 0.83), p=0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.
KW - Glucose-lowering drugs
KW - HIV
KW - Peripheral neuropathy
KW - Risk factors
KW - Symptomatic peripheral neuropathy
UR - http://www.scopus.com/inward/record.url?scp=84867300810&partnerID=8YFLogxK
U2 - 10.1007/s13365-012-0119-9
DO - 10.1007/s13365-012-0119-9
M3 - Article
C2 - 22806348
AN - SCOPUS:84867300810
SN - 1355-0284
VL - 18
SP - 428
EP - 433
JO - Journal of NeuroVirology
JF - Journal of NeuroVirology
IS - 5
ER -